Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Vertical Research Downgrades Huntsman to Hold

Vertical Research Downgrades Huntsman to Hold

Vertical Research analyst Kevin McCarthy downgrades Huntsman (NYSE:HUN) from Buy to Hold.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Vertical Research analyst Kevin McCarthy downgrades Huntsman (NYSE:HUN) from Buy to Hold.

Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10

By Benzinga Newsdesk

February 8, 6:18 AM

Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.

URGN

Gossamer Bio Q2 EPS $(0.74) Up From $(0.80) YoY

By Benzinga Newsdesk

August 9, 8:19 AM

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.74) per share. This is a 7.5 percent increase over losses of $(0.80) per share from the same period last year.

GOSS

Analyst Ratings

Expert Ratings for CrowdStrike Holdings

By Benzinga Insights

November 18, 8:04 AM

CrowdStrike Holdings (NASDAQ:CRWD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CRWD

Procter & Gamble, Royal Caribbean Cruises And 2 Other Stocks Insiders Are Selling

By Lisa Levin

August 2, 8:21 AM

The Nasdaq 100 closed lower on Tuesday. Investors, meanwhile, focused on some notable insider trades.

MCO

Vertical Research Downgrades Huntsman to Hold

Related Posts

Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10

Gossamer Bio Q2 EPS $(0.74) Up From $(0.80) YoY

Expert Ratings for CrowdStrike Holdings

Procter & Gamble, Royal Caribbean Cruises And 2 Other Stocks Insiders Are Selling